[Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor...

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Aberrant epidermal growth factor receptor (EGFR) signaling is common in solid tumors.
• EGFR inhibitors (EGFRIs) are crucial anti-cancer biologic agents.
• EGFRIs include monoclonal antibodies and tyrosine kinase inhibitors targeting EGFR.

Purpose of the Study:

• To review EGFRI-related mucocutaneous adverse reactions.
• To focus on pathogenesis, clinical manifestations, and management strategies.
• To highlight the significance of managing these toxicities for cancer treatment outcomes.

Main Methods:

• Literature review of EGFRI-related mucocutaneous adverse reactions.
• Analysis of pathogenesis and clinical presentations.
• Synthesis of prevention and treatment strategies.

Main Results:

• EGFRIs can cause dose-dependent skin toxicities like rash, paronychia, xerosis, and itch.
• These adverse effects impact patient well-being and treatment adherence.
• Effective management is crucial for optimizing cancer therapy.

Conclusions:

• Understanding EGFRI-induced mucocutaneous reactions is vital.
• Prompt diagnosis and appropriate treatment improve patient care.
• Managing side effects supports continued anti-cancer therapy.